Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Reined-In' US Diagnostics Legislation Adds Pre-Certification, Other Updates

Executive Summary

A revised bill is circulating in both the US House and Senate to revamp FDA regulation of diagnostics. It would allow the agency to leverage a pre-certification process to validate test developers and includes other updates that are likely to appeal to the lab sector. But user fees and other elements could still be contentious.

You may also be interested in...



Q&A: Unpacking The Latest VALID Act For Diagnostics

Covington & Burling partner Scott Danzis tells Medtech Insight why diagnostics developers and labs should keep an eye on the third iteration of the Verifying Accurate, Leading-edge IVCT Development (VALID) Act – reintroduced in the US Senate on 24 June – and why the bill has a better shot at becoming law this time.

If At First You Don’t Succeed: VALID Act For Diagnostics Introduced In Congress For Third Time

The Verifying Accurate, Leading-edge IVCT Development (VALID) Act, which calls for a new regulatory framework for diagnostic tests, has been reintroduced in the US Congress.

US Lawmaker Demands Briefing From HHS Chief On LDT Loophole

Rep. Frank Pallone Jr. calls HHS secretary Alex Azar on the carpet for hobbling the FDA’s oversight of laboratory developed tests.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

MT124372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel